MindMaze Therapeutics completes organizational simplification, exits non-neurology legacy operations
Reuters2026/08/10 05:00- MindMaze Therapeutics completed a corporate reorganization to simplify operations and refocus on its core neurology business.
- The overhaul included disposing of substantially all remaining non-neurology legacy operations obtained via its Relief Therapeutics business combination.
- Transactions used upfront cash consideration with potential future contingent consideration.
- Management expects a lower cost base, simpler structure, improved focus on U.S. commercial priorities, and continued platform development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"I am now the market maker, if you want to bet against me, go ahead" Besant warns the market not to short the yen against him
Bessent stated, "When we intervene in the yen, I know exactly what the Japanese, the Bank of Japan, and Japanese policymakers are going to do." With fundamental support from the Bank of Japan's expected 25 basis point rate hike this month, short-sellers will face the dual pressure of policy intervention and an interest rate shift. Analysts believe that Bessent's tough rhetoric serves both as psychological pressure and as an indication that further actions are being prepared.
South Korean stocks extend gains to over 1%
Flexsteel director William S. Creekmuir sells 3,100 common shares worth $252,891.8
Cerebras CEO Andrew D. Feldman reports sale of USD 7.96 million Class A shares
Crypto prices
More
